Myocardial infarction therapeutic development and pipeline review H1 2015 just published

The report “Myocardial Infarction – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Myocardial Infarction.

Myocardial infarction (MI) (ie, heart attack) is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Approximately 1.5 million cases of Myocardial Infarction occur annually in the United States.

This report is complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies discussed in this report includes: A.

Menarini Industrie Farmaceutiche Riunite Srl, Alligator, Bioscience AB, Amarantus Bioscience Holdings, Inc., Angion Biomedica Corp., Aprogen, Inc., APT Therapeutics, Inc., AstraZeneca PLC, Athersys, Inc., Bayer AG, Bharat Biotech International Limited, BioLineRx, Ltd., Biscayne Pharmaceuticals, Inc., Cardio3 BioSciences SA, Cellmid Limited, CellProthera

Compugen Ltd., CSL Limited, FibroGen, Inc., Fina Biotech, Genextra S.p.a., GlaxoSmithKline plc, GliaMed, Inc., Hadasit Medical Research Services & Development Ltd, Human Stem Cells Institute, HUYA Bioscience International, LLC, Immune Pharmaceuticals, Ltd., Inbiopro Solutions Pvt. Ltd., Juventas Therapeutics, Inc., Laboratoires Pierre Fabre SA, Lacer, S.A., Lee's Pharmaceutical Holdings Limited, LegoChem Biosciences, Inc, LG Life Sciences, Ltd., Ligand Pharmaceuticals, Inc., Medestea Research & Production S.p.A., Merck & Co., Inc., Mesoblast Limited, miRagen Therapeutics, Inc., NeoStem, Inc., NeuroVive Pharmaceutical AB, Omeros Corporation, Omni Bio Pharmaceutical Inc., Pluristem Therapeutics Inc., Polyphor Ltd., Quantum Genomics SA, Recardio GmbH, Remedy Pharmaceuticals, Inc., Serodus ASA, STELIS Biopharma Pvt. Ltd., Stemedica Cell Technologies, Inc., Stempeutics Research Private Limited, TaiGen Biotechnology Co., Ltd., Targazyme, Inc., Vicore Pharma AB, Zydus Cadila Healthcare Limited.

Drug Profiles discussed in this report include: ADC-1004, Alpha-1 Antitrypsin, amediplase, AMR-001, AMRS-001, ANG-4011, AP-102, APT-102, Biglycan Therapy for Cardiovascular Diseases, Biosimilar 3 for Rheumatoid Arthritis and Acute Myocardial Infarction, Biosimilar 4 for Acute Myocardial Infarction and Infertility, BIS-5409, BL-7060, Bone Marrow Derived Mononuclear Cells for Cardiovascular Diseases, BQ-123, burixafor, C-21, C3BSGQR-3, C3BSGQR-4, CAP-1001, CAP-1002, cenderitide, CGEN-856, CGEN-856S, CGEN-857, CIGB-500, clopidogrel bisulfate, CM-1, CMK-103, Cryocell, CSL-112, CTX-101, CTX-201, Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders, Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction, Ephrin A-1, F-573, Fc-Alpha-1 Antitrypsin, FcAAT-2, FcAAT-3, FG-6874, Gemacell, Gene Therapy for Acute Myocardial Infarction, glyburide, GM-1485, HBI-3802, HYPER-IL-6, IBPB-005ET, ICG-001, JI-38, JVS-100, JVS-200, LA-8045, LC-280126, losmapimod, Mesenchymal Stem Cells, MGN-1374, MGN-6114, Monoclonal Antibody Conjugates to Target Mannose Receptor for Myocardial Infarction, MPC-150IM, MTP-131, MultiStem, NL-005, NVP-019, Oligonucleotide for Oncology and Cardiovascular, Oligonucleotides for Cardiometabolic Diseases and Renal diseases, OMS-721, Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction, POL-6326, Polyglactin 370 for Acute Myocardial Infarction, ProtheraCytes, QGC-101, REC-01, RNAi Oligonucleotide for Myocardial Infarction, Synthetic Peptide for Cardiovascular Diseases, Stempeucel, THR-100, ticagrelor, TZ-101, VN-100, ZK-001.

Complete report available @ http://www.rnrmarketresearch.com/myocardial-infarction-pipeline-review-h1-2015-market-report.html .